ArticleImmunity, inflammation and disease2026
DUSP1 Attenuates Renal Injury in Diabetic Nephropathy by Modulating Ferroptosis: Evidence From Animal Experiments.
Article in Immunity, inflammation and disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- DUSP family phosphatases in cell signaling, inflammation, and chronic diseases.Journal of biomedical science · 2026Review
- DUSP1 Attenuates Renal Injury in Diabetic Nephropathy by Modulating Ferroptosis: Evidence From Animal Experiments.Immunity, inflammation and disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectiveEmerging evidence suggests that ferroptosis contributes significantly to the progression of diabetic nephropathy (DN). This study aimed to explore the potential association between dual specificity phosphatase 1 (DUSP1) and ferroptosis in a streptozotocin-induced DN rat model.
methodsWe analyzed microarray datasets (GSE30122 and GSE96804) from the gene expression omnibus (GEO) database to identify ferroptosis-related differentially expressed genes (FDEGs), with particular focus on DUSP1. Experimental validation was performed using 45 specific pathogen-free Sprague-Dawley rats: 15 controls and 30 STZ-induced DN models (60 mg/kg, i.p.). After 12 weeks, successfully modeled rats (n = 28) were randomized into DN (n = 14) and DN+Ferrostatin-1 (Fer-1, a ferroptosis inhibitor, 2.5 μmol/kg, n = 14) groups. Renal function parameters (blood urea nitrogen, serum creatinine, urinary albumin) were quantified using automated biochemical analysis. Renal tissue antioxidant capacity (SOD, GSH, MDA) and iron content were assessed. Histopathological evaluation employed HE, Masson, PAS, and Lillie staining. DUSP1 expression was analyzed via immunohistochemistry, Western blot, and RT-qPCR.
resultsDN rats exhibited characteristic metabolic disturbances including polydipsia (394.32 ± 9.92 vs. 28.84 ± 2.45 mL/day, p < 0.001), polyuria, and progressive weight loss. Renal function impairment was evidenced by elevated blood urea nitrogen (2.50 ± 0.46 vs. 11.61 ± 1.61 mmol/L, p < 0.001), serum creatinine (43.01 ± 5.81 vs. 107.62 ± 9.90 μmol/L, p < 0.001), and urine albumin-to-creatinine ratio (18.53 ± 0.92 vs. 269.97 ± 24.59 mg/g, p < 0.001). Fer-1 treatment significantly ameliorated these parameters (p < 0.05) and reduced histopathological damage. DN rats exhibited significantly reduced DUSP1 expression and increased ferroptosis-associated alterations, including elevated ACSL4 expression, enhanced lipid peroxidation, and impaired antioxidant capacity, all of which were partially reversed by Fer-1 treatment (p < 0.001).
conclusionsOur findings indicate that inhibition of ferroptosis attenuates renal injury in DN and is accompanied by altered DUSP1 expression. These results suggest a potential association between ferroptosis regulation and DUSP1 in DN, providing new insight into ferroptosis-related mechanisms involved in disease progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.